AXL in metastatic ovarian cancer tumors is a targetable biomarker associated with chemoresistance and poor prognosis

MLA

C.K. McCourt, et al. “AXL in Metastatic Ovarian Cancer Tumors Is a Targetable Biomarker Associated with Chemoresistance and Poor Prognosis.” Gynecologic Oncology, vol. 154, June 2019, pp. 79–80. EBSCOhost, https://doi.org/10.1016/j.ygyno.2019.04.188.

APA

C.K. McCourt, J.M. Quinn, Premal H. Thaker, G. Opara, A.R. Hagemann, M. Greenwade, H. Beck-Noia, David G. Mutch, Ian S. Hagemann, Mary M. Mullen, K.C. Fuh, L.M. Kuroki, & M.A. Powell. (2019). AXL in metastatic ovarian cancer tumors is a targetable biomarker associated with chemoresistance and poor prognosis. Gynecologic Oncology, 154, 79–80. https://doi.org/10.1016/j.ygyno.2019.04.188

Chicago

C.K. McCourt, J.M. Quinn, Premal H. Thaker, G. Opara, A.R. Hagemann, M. Greenwade, H. Beck-Noia, et al. 2019. “AXL in Metastatic Ovarian Cancer Tumors Is a Targetable Biomarker Associated with Chemoresistance and Poor Prognosis.” Gynecologic Oncology 154 (June): 79–80. doi:10.1016/j.ygyno.2019.04.188.